{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:43Z","timestamp":1793817583303,"version":"4.6.1"},"reference-count":39,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The in-clinic phosphatidylinositol 3-kinase (PI3K) inhibitors idelalisib (CAL-101) and duvelisib (IPI-145) have demonstrated high rates of response and progression-free survival in clinical trials of B-cell malignancies, such as chronic lymphocytic leukemia (CLL). However, a high incidence of adverse events has led to frequent discontinuations, limiting the clinical development of these inhibitors. By contrast, the dual PI3K\u03b4\/casein kinase-1-\u03b5 (CK1\u03b5) inhibitor umbralisib (TGR-1202) also shows high rates of response in clinical trials but has an improved safety profile with fewer severe adverse events. Toxicities typical of this class of PI3K inhibitors are largely thought to be immune mediated, but they are poorly characterized. Here, we report the effects of idelalisib, duvelisib, and umbralisib on regulatory T cells (Tregs) on normal human T cells, T cells from CLL patients, and T cells in an E\u03bc-TCL1 adoptive transfer mouse CLL model. Ex vivo studies revealed differential effects of these PI3K inhibitors; only umbralisib treatment sustained normal and CLL-associated FoxP3+ human Tregs. Further, although all 3 inhibitors exhibit antitumor efficacy in the E\u03bc-TCL1 CLL model, idelalisib- or duvelisib-treated mice displayed increased immune-mediated toxicities, impaired function, and reduced numbers of Tregs, whereas Treg number and function were preserved in umbralisib-treated CLL-bearing mice. Finally, our studies demonstrate that inhibition of CK1\u03b5 can improve CLL Treg number and function. Interestingly, CK1\u03b5 inhibition mitigated impairment of CLL Tregs by PI3K inhibitors in combination treatment. These results suggest that the improved safety profile of umbralisib is due to its role as a dual PI3K\u03b4\/CK1\u03b5 inhibitor that preserves Treg number and function.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001800","type":"journal-article","created":{"date-parts":[[2020,7,7]],"date-time":"2020-07-07T16:05:13Z","timestamp":1594137913000},"page":"3072-3084","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":63,"title":["The dual PI3K\u03b4\/CK1\u03b5 inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2721-1188","authenticated-orcid":false,"given":"Kamira","family":"Maharaj","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology,"},{"name":"Department of Immunology, and"},{"name":"Department of Cancer Biology PhD Program, University of South Florida and H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-2645","authenticated-orcid":false,"given":"John J.","family":"Powers","sequence":"first","affiliation":[{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Achille","sequence":"first","affiliation":[{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Mediavilla-Varela","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology,"},{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Gamal","sequence":"first","affiliation":[{"name":"Department of Immunology, and"},{"name":"Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3805-9580","authenticated-orcid":false,"given":"Karen L.","family":"Burger","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9839-6984","authenticated-orcid":false,"given":"Renee","family":"Fonseca","sequence":"first","affiliation":[{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8531-7813","authenticated-orcid":false,"given":"Kun","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari P.","family":"Miskin","sequence":"first","affiliation":[{"name":"TG Therapeutics, Inc., New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Maryanski","sequence":"first","affiliation":[{"name":"TG Therapeutics, Inc., New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-1822","authenticated-orcid":false,"given":"Andrii","family":"Monastyrskyi","sequence":"first","affiliation":[{"name":"Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek R.","family":"Duckett","sequence":"first","affiliation":[{"name":"Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9785-5897","authenticated-orcid":false,"given":"William R.","family":"Roush","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, The Scripps Research Institute, Scripps Florida, Jupiter, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Cleveland","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-2275","authenticated-orcid":false,"given":"Eva","family":"Sahakian","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology,"},{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"first","affiliation":[{"name":"Department of Malignant Hematology,"},{"name":"Department of Immunology, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,7,7]]},"reference":[{"key":"2020070711395898600_B1","first-page":"123","article-title":"PI3K signaling in normal B cells and chronic lymphocytic leukemia (CLL)","volume":"393","author":"Okkenhaug","year":"2016","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"2020070711395898600_B2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1600-065X.2010.00934.x","article-title":"Role of PI3K in the generation and survival of B cells","volume":"237","author":"Werner","year":"2010","journal-title":"Immunol Rev"},{"issue":"1","key":"2020070711395898600_B3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1034\/j.1600-065X.2000.00611.x","article-title":"Regulation of B-cell activation and differentiation by the phosphatidylinositol 3-kinase and phospholipase Cgamma pathway","volume":"176","author":"Marshall","year":"2000","journal-title":"Immunol Rev"},{"issue":"5583","key":"2020070711395898600_B4","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1126\/science.1073560","article-title":"Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice","volume":"297","author":"Okkenhaug","year":"2002","journal-title":"Science"},{"key":"2020070711395898600_B5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fimmu.2012.00245","article-title":"The role of the PI3K signaling pathway in CD4(+) T cell differentiation and function","volume":"3","author":"Han","year":"2012","journal-title":"Front Immunol"},{"issue":"11","key":"2020070711395898600_B6","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/2326-6066.CIR-17-0143","article-title":"PI3K\u03b3 activates integrin \u03b14 and promotes immune suppressive myeloid cell polarization during tumor progression","volume":"5","author":"Foubert","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"7629","key":"2020070711395898600_B7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","article-title":"PI3K\u03b3 is a molecular switch that controls immune suppression [published correction appears in Nature. 2017;542(7639):124]","volume":"539","author":"Kaneda","year":"2016","journal-title":"Nature"},{"issue":"6","key":"2020070711395898600_B8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.seminoncol.2016.11.011","article-title":"PI3K signaling pathway in normal B cells and indolent B-cell malignancies","volume":"43","author":"Pongas","year":"2016","journal-title":"Semin Oncol"},{"issue":"3","key":"2020070711395898600_B9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"2020070711395898600_B10","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.3109\/10428194.2015.1022770","article-title":"Management of adverse events associated with idelalisib treatment: expert panel opinion","volume":"56","author":"Coutr\u00e9","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2020070711395898600_B11","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2016-08-731240","article-title":"Silencing c-Myc translation as a therapeutic strategy through targeting PI3K\u03b4 and CK1\u03b5 in hematological malignancies","volume":"129","author":"Deng","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2020070711395898600_B12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S1470-2045(18)30082-2","article-title":"Umbralisib, a novel PI3K\u03b4 and casein kinase-1\u03b5 inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study","volume":"19","author":"Burris","year":"2018","journal-title":"Lancet Oncol"},{"issue":"11","key":"2020070711395898600_B13","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1080\/13543784.2017.1384815","article-title":"PI3K\u03b4-selective and PI3K\u03b1\/\u03b4-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma","volume":"26","author":"Lampson","year":"2017","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"2020070711395898600_B14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/blood-2016-03-707133","article-title":"Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity","volume":"128","author":"Lampson","year":"2016","journal-title":"Blood"},{"key":"2020070711395898600_B15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1182\/blood-2018-99-117526","article-title":"Phase I\/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed\/refractory CLL and Richter\u2019s transformation","volume":"132","author":"Mato","year":"2018","journal-title":"Blood"},{"issue":"21","key":"2020070711395898600_B16","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/bloodadvances.2017006809","article-title":"Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia","volume":"1","author":"Maharaj","year":"2017","journal-title":"Blood Adv"},{"issue":"25","key":"2020070711395898600_B38","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"issue":"12","key":"2020070711395898600_B33","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","article-title":"Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals","volume":"116","author":"Herman","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2020070711395898600_B34","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1038\/leu.2015.105","article-title":"The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (duvelisib), overcomes signals from the PI3K\/AKT\/S6 pathway and promotes apoptosis in CLL","volume":"29","author":"Balakrishnan","year":"2015","journal-title":"Leukemia"},{"issue":"2","key":"2020070711395898600_B23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1124\/jpet.109.151415","article-title":"Selective inhibition of casein kinase 1 epsilon minimally alters circadian clock period","volume":"330","author":"Walton","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"issue":"15","key":"2020070711395898600_B39","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1073\/pnas.0901166106","article-title":"E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction","volume":"106","author":"Gorgun","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"issue":"27","key":"2020070711395898600_B17","doi-asserted-by":"crossref","first-page":"42826","DOI":"10.18632\/oncotarget.8753","article-title":"GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-\u03b2 releasing","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"key":"2020070711395898600_B18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fimmu.2013.00163","article-title":"The role of regulatory T cells in the biology of graft versus host disease","volume":"4","author":"Beres","year":"2013","journal-title":"Front Immunol"},{"key":"2020070711395898600_B19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ceb.2014.08.003","article-title":"Casein kinase 1 and Wnt\/\u03b2-catenin signaling","volume":"31","author":"Cruciat","year":"2014","journal-title":"Curr Opin Cell Biol"},{"issue":"14","key":"2020070711395898600_B20","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1128\/MCB.01466-10","article-title":"Coordinated action of CK1 isoforms in canonical Wnt signaling","volume":"31","author":"Del Valle-P\u00e9rez","year":"2011","journal-title":"Mol Cell Biol"},{"issue":"22","key":"2020070711395898600_B21","doi-asserted-by":"crossref","first-page":"12548","DOI":"10.1073\/pnas.96.22.12548","article-title":"Casein kinase iepsilon in the wnt pathway: regulation of beta-catenin function","volume":"96","author":"Sakanaka","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"2020070711395898600_B22","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1158\/1078-0432.CCR-10-0356","article-title":"Wnt\/beta-catenin signaling in T-cell immunity and cancer immunotherapy","volume":"16","author":"Gattinoni","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2020070711395898600_B24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.immuni.2013.07.019","article-title":"Canonical Wnt signaling negatively modulates regulatory T cell function","volume":"39","author":"van Loosdregt","year":"2013","journal-title":"Immunity"},{"issue":"7","key":"2020070711395898600_B25","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat Med"},{"issue":"5","key":"2020070711395898600_B26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2018.28","article-title":"Targeting the PI3K pathway in cancer: are we making headway?","volume":"15","author":"Janku","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"2020070711395898600_B27","first-page":"913","article-title":"BCL-1 rearrangements and p53 mutations in atypical chronic lymphocytic leukemia with t(11;14)(q13;q32)","volume":"85","author":"De Angeli","year":"2000","journal-title":"Haematologica"},{"issue":"11","key":"2020070711395898600_B28","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V95.11.3534","article-title":"Somatic mutation of bcl-6 genes can occur in the absence of V(H) mutations in chronic lymphocytic leukemia","volume":"95","author":"Sahota","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2020070711395898600_B29","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1038\/bcj.2017.40","article-title":"Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment","volume":"7","author":"Paulus","year":"2017","journal-title":"Blood Cancer J"},{"issue":"4","key":"2020070711395898600_B30","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/bjh.13427","article-title":"Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"170","author":"Zhang","year":"2015","journal-title":"Br J Haematol"},{"issue":"7","key":"2020070711395898600_B31","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020070711395898600_B32","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"issue":"2","key":"2020070711395898600_B35","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3390\/ph12020069","article-title":"Duvelisib: a 2018 novel FDA-approved small molecule inhibiting phosphoinositide 3-kinases","volume":"12","author":"Rodrigues","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"issue":"24","key":"2020070711395898600_B36","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2014-07-587279","article-title":"IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells","volume":"124","author":"Dong","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020070711395898600_B37","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1182\/blood-2017-05-786947","article-title":"Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia","volume":"131","author":"Janovska","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3072\/1748120\/advancesadv2020001800.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/3072\/1748120\/advancesadv2020001800.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T16:40:56Z","timestamp":1667320856000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/3072\/461272\/The-dual-PI3K%CE%B4CK1%CE%B5-inhibitor-umbralisib-exhibits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,7]]},"references-count":39,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001800","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,7]]}}}